Skip to main content
. Author manuscript; available in PMC: 2021 Jan 16.
Published in final edited form as: Vaccine. 2019 Oct 31;38(3):644–654. doi: 10.1016/j.vaccine.2019.10.049

Table 4.

Survival following lethal MPXV challenge.

Study ID Study Group Assignment MPXV Target Challenge Dose (PFU, IV) Survival
Study 1 Controls 5.0E+07 0/3
ACAM2000 + Placebo 5.0E+07 6/6
ACAM2000 + Tecovirimat 5.0E+07 7/7
Study 2 ACAM2000 + Placebo 5.0E+07 3/3
ACAM2000 + Tecovirimat 5.0E+07 2/3
Study 3 ACAM2000 + Placebo 5.0E+07 3/3
ACAM2000 + Tecovirimat 5.0E+07 3/3